Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension (GMRx2_ACT)
Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Dual Combinations for the Treatment of Hypertension
Sponsor: George Medicines PTY Limited
Listed as NCT04518293, this PHASE3 trial focuses on Hypertension and remains completed. Sponsored by George Medicines PTY Limited, it has been updated 16 times since 2021, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2024 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 11 earlier versions
-
Jan 2024 — May 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Nov 2022 — Jan 2024 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- George Medicines PTY Limited
For direct contact, visit the study record on ClinicalTrials.gov .